Please assess the completion status of the following clinical trial:

Trial Title: Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients may participate in the study if they have/are~* Patients aged 18-95 years who have provided written informed consent.~* Patients requiring skin grafting due to burns, trauma, chronic venous ulcers, or surgical removal of cutaneous malignancies with a donor site expected to be between 8 and 200 cm2 on a non-articulated area.~* Patient is prepared to comply with all study requirements, including the following:~  * Application of Oleogel-S10 on the SSG at every change of wound dressing;~ * Regular clinic visits during the treatment period, and follow-up period.~* Negative pregnancy test of women of childbearing potential performed within 7 days prior to the start of treatment.~* Women of childbearing potential must agree to use an effective method of contraception (Pearl-Index \< 1, e.g. hormonal contraception including the combined oral contraceptive pill, the transdermal patch, and the contraceptive vaginal ring, intrauterine devices or sterilization) during treatment and for at least 6 months thereafter.~* Men must agree to use an effective method of contraception during treatment and for at least 6 months thereafter.~Exclusion Criteria:~Patients will be excluded from the study if they have/are~* burns involving more than 15% of their total body area;~* sepsis, haemodynamic instability requiring pressor support or positive blood microbiology cultures within 48h of surgery;~* inhalation injury requiring artificial respiratory assistance;~* requiring skin grafts following removal of suspicious skin lesions;~* received treatment with systemic steroids during the 30 days prior to surgery;~* uncontrolled diabetes or diabetic ulcers;~* diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerance or efficacy;~* previously skin grafts harvested from the area to be studied;~* a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial;~* a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial;~* known multiple allergic disorders;~* taking, or have taken, any investigational drugs within 3 months prior to the screening visit;~* undergoing investigations or changes in management for an existing medical condition;~* not likely to complete the trial for whatever reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- experimantal: wound site will be treated with Oleogel-S10 (Type: EXPERIMENTAL): The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10.~Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg~Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg~* Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)~* Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
- Moist wound healing dressing alone (Type: ACTIVE_COMPARATOR): Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site

Based on this trial design, predict the completion outcome and termination type (if applicable).